For a single year, 1983, we compared the actual and estimated morbidity, mortality, and costs attributable to measles, mumps, and rubella with having or not having a childhood immunization program using the combined measles-mumps-rubella (MMR) vaccine. Without an immunization program, an estimated 3,325,000 cases of measles would occur as compared to 2,872 actual cases in 1983 with a program. Instead of an expected 1.5 million rubella cases annually, there were only 3,816 actual cases. Mumps cases were lowered from an expected 2.1 million to 32,850 actual cases. Comparable reductions in disease-associated complications,
Introduction
Licensure of measles, mumps, and rubella vaccines has led to the vaccination of millions of children and dramatic reductions in the morbidity and mortality associated with these diseases." Benefit-cost analyses have been used to evaluate the economic impact of these immunization programs. Most previous studies analyzing immunization against individual diseases with single antigen vaccine demonstrated benefit-cost ratios ranging between 5 and 12:1, depending on the techniques and assumptions used. 9 Since these studies, there has been greater experience and considerable success in controlling these diseases. Immunization is now usually accomplished with combination measlesmumps-rubella vaccine, MMR. The purpose of this study is to compare the relative benefits and costs for an MMR immunization program with the alternative of no immunization program, and with vaccination using individual measles, mumps, and rubella antigens.
Methods
Our model assessed the morbidity, mortality, and costs attributable to measles, rubella, and mumps in 1983 with an immunization program, as compared to projected outcomes for a hypothetical situation in 1983 had there not been an immunization program. To estimate the number of cases of measles, mumps, or rubella that would have occurred in 1983 without a vaccination program, we made the following estimates and assumptions.
In the absence of a vaccination program, members of a birth cohort become infected at different ages based on the epidemiologic characteristics of the disease. Age-specific infection rates can be determined either from the seroprevalence of antibodies to the agent by age, or from historical surveys which determine the age at which infection occurred. For example, in the case of measles we know that prior to the initiation of vaccination programs 95 per cent of individuals in an unvaccinated population have evidence of infection by age 30.10,11 We assume that the number of susceptible sequelae, and deaths are gained with an immunization program. Without a vaccination program, disease costs would have been almost $1.4 billion. Based on the actual incidence of disease in 1983, costs were estimated to be approximately $14.5 million. Expenditures for immunization, including vaccine administration costs and the costs associated with vaccine reactions, totaled $% million. The resulting benefit-cost ratio for the MMR immunization program is approximately 14:1. The savings realized due to the use of combination rather than single antigen vaccine total nearly $60 million. (Am J Public Health 1985; 75:739-744.) persons entering the population annually was constant 3.5 million, the average of the annual number of births in the United States from 1976-8.12 A steady-state condition is created where the annual input of susceptible individuals into the population is balanced by an approximately equal number of individuals leaving the study population having reached age 30 (95 per cent of whom would be immune to measles). Thus, in this steady-state, the number of individuals infected by measles annually would be equivalent to 95 per cent of 3.5 million, with an age distribution of cases proportional to the age-specific infection rates. Similar estimates can be made for rubella and mumps. This hypothetical situation is contrasted to the actual situation in 1983, the most recent year for which complete data are available, and one which we assume to be representative of morbidity, mortality, and immunization program costs.
The costs of disease include expenditures made for treatment of acute illness, complications and chronic sequelae, lost wages from missed work, and lifetime earnings lost due to retardation or death. The "benefits" of a vaccination program are savings in costs that would have been incurred to treat the disease and its complications had it not been prevented. Costs of immunization are the expenditures made for vaccine and its administration, treatment of vaccine-associated complications, and implementation of immunization programs. A benefit to cost (B/C) ratio is calculated by dividing the difference in costs of disease with and without an immunization program by the costs of the immunization program [i.e., B/C = (disease costs without an immunization program minus disease costs with an immunization program)/costs of the immunization program]. Expenditures counted as benefits or costs made in different years have been adjusted to their 1983 value using a discount rate of 10 per cent per annum. Wherever possible, documented figures for rates of illness, complications, and costs have been used. If published sources were not available, estimates were made with the assistance of experts in the epidemiology of vaccine-preventable diseases. In making estimates and assumptions, we tended to underestimate the benefits of the vaccines, thus providing a "lower bound" estimate of vaccine benefit. Most of our assumptions have been used in previous benefit-cost analyses and, to facilitate comparability, we have used similar figures where appropriate.
Measles, Rubeila, and Mumps Specific estimates and assumptions were made in calculating disease incidence, frequency of complications, and costs, and are summarized in Appendix I. Cases predicted in the absence of a vaccination program were calculated according to the method described above. Cases having actually occurred in 1983 were calculated based on reported cases and the estimated reporting efficiency. Estimated incidence of complications was calculated using our estimated number of cases, and commonly accepted, published rates for complications. Complication rates were considered to be equal in both vaccinated and unvaccinated populations.
Direct costs included physician visits, hospitalization, supportive medical care, special schooling, and institutionalization. Indirect costs included wages lost from missed work, and lifetime earnings lost due to retardation or death. We calculated time lost from work, considering that in 1983 approximately 65 per cent of women between the ages of 20 and 40 were employed'2 and that, in those families where both parents were employed, one of the parents would be required to take time offfrom work to stay at home with a sick child.
Costs of Immunization
Costs for the immunization program included expenditures for public sector immunization programs, for private immunization, and for vaccine-related reactions requiring medical consultation. One-half of all children were assumed to receive their immunization from a private practitioner. Vaccine and program cost estimates were provided by the Immunization Division, Centers for Disease Control. Federal and state costs for immunization programs were estimated based on federal expenditures and grants to states. Costs for local health departments were assumed to be equal to one-half state and federal expenditures for immunizations.
Results
An MMR immunization program is associated with a considerable reduction in the morbidity and mortality associated with measles, rubella, and mumps in 1983 when compared to a situation without an MMR vaccination program ( Table 1) .
Cases of measles decreased from an expected 3,325,000 to 2,872 cases, while measles-related mortality was reduced from 366 deaths to less than one; the number of children handicapped by the neurological sequelae of measles decreased from 291 to less than one. Comparable impressive reductions are documented for rubella and mumps and their associated complications and mortality in Table 1 .
Costs associated with measles, rubella, and mumps in 1983 totaled nearly $14.5 million with a vaccination program, as contrasted to $1.4 billion in the absence of a vaccination program ( Table 2 ). Reduction in morbidity and mortality costs attributable to measles totaled almost $670 million. For rubella, the comparable figure is almost $380 million; for mumps it is almost $340 million. The total reduction in morbidity and mortality costs amounts to almost $1.3 billion.
The overall cost estimates for morbidity and mortality associated with measles, rubella, and mumps both in the absence and presence ofa vaccination program, as well as the costs ofthe nationwide MMR immunization program in 1983, are summarized in Table 3 . The estimated costs for both public and private MMR immunizations totaled about $94 million. Costs related to adverse vaccine reactions were about $2 million. The benefit-cost ratio for MMR immunization programs is 14.4:1. Using the same methodology, but assuming single antigen vaccine, the benefit-cost ratios for measles, rubella, and mumps were 11.9:1, 7.7:1, and 6.7:1, respectively ( Table 3 ). The savings realized due to the use of combined versus single antigen vaccine total nearly $60 million.
Discussion
This study demonstrates the tremendous reductions in morbidity, mortality, and financial expenditures realized as a result of the measles, rubella, and mumps immunization programs. With both measles and mumps, the greatest financial benefit is gained predominantly from savings associated with uncomplicated illness (the majority of which are indirect costs). The most significant cost factors associated with rubella are related to the long-term sequelae of congenital rubella.
The resulting benefit-cost ratio of over 14:1 is of such magnitude that even if particular assumptions and rates used in our calculations are thought to be incorrect, wide latitude exists for altering these estimates while still yielding a high benefit-cost ratio. We selectively altered a variety of our assumptions in an effort to test the sensitivity ofour analyses. Altering the values for single variables had a negligible impact on the overall benefit-cost ratio. Increasing the actual number of cases of measles, mumps, and rubella occurring with a vaccination program by a factor of four still produced a benefit-cost ratio of 13.9:1. Indirect costs comprise a large proportion of the expenditures associated with these diseases. Excluding indirect costs completely, the resulting benefit-cost ratio would be approximately 3.0:1. While immunization is associated with significant reductions in all disease-related complications, this effect is not necessarily equal and proportional in all cases. The ratio of congenital rubella syndrome (CRS) to rubella cases differs with and without a vaccination program, 40:3816 (or 1:95) compared to 2000:1,487,500 (or 1:744). The higher ratio of CRS cases to overall rubella cases with a vaccination program reflects the altered age-distribution of cases when there is an immunization program. With an immunization program, a greater proportion of the infections occur in young adults, and thus there is a proportionate increase in the number of infections in pregnant women although the absolute number of cases is markedly reduced.
In our calculations, we did not make allowances for the possibility that pregnant women contracting rubella might choose to terminate their pregnancy. This would alter the costs which largely can be attributed to CRS. However, even if as many as 90 per cent of those at risk had abortions, without any cost attributed to the procedures and care, the overall benefit-cost ratio would still be almost 12.5:1. Of course, this calculation as with the others in this anilysis does not consider the intangible losses of grief and suffering.
The model also allows us to compare the benefit-cost ratios for separate immunizations with single antigen vaccines (M + M + R) with that of combined vaccine using our same model. We assumed that public program costs remained unchanged. The calculated benefit-cost ratio for combined vaccine substantially exceeds the benefit-cost ratios for the individual components. The savings using combined vaccine are primarily generated as a result of reduced physician visits, more efficient administration, less expensive vaccine costs, and a lower overall number of adverse vaccine reactions. Other advantages not given economic credits in this study include more uniform coverage, with a reduction in the number of both missed and reimmunized individuals, and reduced administrative and personnel requirements.
While this study demonstrates the added benefit realized from the use of combination as opposed to single antigen vaccine, the benefits of combination vaccine have been underestimated in our model. We did not consider that there was any decrease in public expenditures for immunization with combination vaccine. Yet, we know that in 1983 approximately 10 per cent of vaccine used in public immunization programs was single antigen; if only combination vaccine was used, there would have been an additional savings of $320,000 in vaccine costs, as well as additional savings from fewer physician visits and other administrative costs.
Combined measles, mumps, and rubella vaccine (MMR) has been available in the United States since 1971. Seroconversion rates and reaction rates are not significantly different from those occurring when the antigens were administered separately at different times.2S32 Despite the fact that there are no valid scientific reasons for using the three single antigen products in persons likely to be susceptible to multiple components, these individual antigens continue to be used in some settings, requiring the patient to make multiple visits before protection against the three diseases is assured.
Vaccination policy for rubella control varies from country to country. In the United States, the goal has been to interrupt or curtail transmission by universal vaccination of infants and young children. 33 This allows administration of rubella vaccine with measles and mumps simultaneously in a single vaccine for infants, resulting in marked economic savings compared to use of the single antigens. Other countries such as the United Kingdom vaccinate females approaching puberty. This means that separate visits are needed for measles vaccine in infancy and rubella vaccine in [11] [12] year old girls. While many factors must be considered in determining vaccination policies for rubella control including accessibility of target populations, vaccine safety and efficacy, and coverage rates, the savings afforded through use ofcombined vaccines should be considered in those countries embarking on or continuing rubella control programs.
Although not directly comparable due to differences in the models used, our results parallel and are supported by earlier studies.924 While individually all these programs show impressive benefits, there is substantial financial advantage to the use of combined vaccine (MMR). Our study clearly demonstrates the extraordinary benefits of a combined measles, rubella, and mumps immunization program in reducing both the burden of illness and its resulting costs.
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